In the Life organization, we established the business vision "We will lead the world in advancing Bio Industrial Autonomy and contribute to a future embracing global harmony" with the aim of clarifying future developments of the business, its scope and direction. In this vision, we have targeted the "Pharmaceutical, Food, Beverage & Biotech" sectors and aim to further expand our business, centering on these industries, by taking advantage of our strengths in "Measurement, Imaging, Analysis, Diagnosis, Integration" and Yokogawa core technologies.
By contributing to the development of measurement and analysis technologies, we will solve problems that limit research progress and create a world where scientists can concentrate on science.
Using real-time monitoring and software innovations, we will create a virtual world of "Digital Twin" where experimental simulations are leveraged to realize precision predictive control
We analyze and control the information obtained from all manufacturing activities and solve issues related to raw material quality, facility degradation, transmission of technology, and production processes to improve work environment and worker safety.
In addition to improving optimal and efficient automatic processes based on demand forecasting, we will assist with quality improvements that include taste attributes, and promote autonomous operation that grows independent of human intervention.
Water & Wastewater
Yokogawa supports a wide range of water control applications in both the municipal and industrial water markets.
We have 30 years of experience in this life science field and will respond to customer's problem solving with cutting-edge solutions.
YOKOGAWA is working on the development of single cell mass spectrometry and single cell gene analysis. In order to analyze one cell with high sensitivity, we are developing a method of collecting target cells while keeping position information under observing cells with confocal scanner.
Yokogawa's in-line sensors and advanced control algorithms will stabilize and improve the efficiency of the cell culture processes for biopharmaceutical production.
The OpreX™ Environmental Monitoring System collects, measures, and stores temperature and humidity as well as other management data for comprehensive oversight of the pharmaceutical manufacturing, quality control, and storage areas.
Yokogawa is a proponent of a robust genetic testing method for food, drink, and drug contamination that can be carried out with overwhelming speed and simplicity.
Yokogawa is contributing to the development of the pharmaceutical industry based on its performance of introducing over 1,000 systems in the areas of drug substances, pharmaceutical products, and biotechnology.
In addition to daily improvement cycles, Yokogawa will use IIoT to support create environments that do not cause defects and that are designed to completely reduce losses.
Life Business Headquarters’ contribution towards the fight against Novel Coronavirus Disease (COVID-19)
Yokogawa established the Life Business Headquarters with the goal of promoting well-being for all. In addition to engaging in our existing life science and manufacturing solutions businesses targeting the pharmaceutical and food industries, the headquarters works to develop new products and services and provides one-stop solutions that revolutionize productivity throughout the pharmaceutical and food industry value chain, from basic research to manufacturing, logistics, and services.
Yokogawa has more than 30 years’ experience in the life science field. The CSU spinning disk confocal scanner series is our core strength, and over 3,000 units have been sold globally. Other products, including a live cell imaging system, a high-content analysis system and single cell analysis solution also support leading life science studies. In the field of manufacturing solutions, over 1,000 Yokogawa manufacturing, production, and quality management systems and control systems have been introduced in the pharmaceutical industry.
In response to the novel coronavirus (COVID-19), Yokogawa has been taking various measures to prevent transmission of the virus while working to minimize the impact on customers. We are also contributing to the fight against COVID-19 by collaborating with research institutes globally and supporting research to develop new medication or vaccines. Yokogawa will continue to work with customers and business partners in an effort to resolve the crisis society is facing.
Please contact our sales and service representatives if you have any interest in our products, or you can send inquiries from the form below.
Sales Release : Single CellomeTM System SS2000
We announce the sales release of Single Cellome System SS2000 on February 18th, 2022.
Please contact us for the details.
Sales release : Confocal Quantitative Image Cytometer CellVoyager CQ1 new option and latest software were released
Sales release : CellPathfinder new product and the latest software were released
Yokogawa Develops Single Cellome System SS2000 for Intracellular Sampling
＜Features of the SS2000＞
The SS2000 will be released to the Japan, US and China market in January 2022, with release in other markets such as Europe to follow at a later date.
Yokogawa Acquires Insilico Biotechnology, Developer of Innovative Bioprocess Digital Twin Technology
Yokogawa Electric Corporation acquires Insilico Biotechnology a developer and provider of bioprocess software and services.
Sales release : Advanced Control Bioreactor System BR1000 was released.
YOKOGAWA Sponsored Webinar
Bioprocessing Summit 2020 Virtual
Dates: August 24-28 EST, 2020
Yokogawa introduce about advanced automated bioreactor controller system. Join us at our virtual tradeshow booth. We look forward to connecting with you.
Discovering Potential Covid-19 Therapies using High Content Screening
YOKOGAWA Sponsored Webinar
July 29, 2020 11 am to 12 pm EDT (July 30, 2020 0 am to 1 am JST)
Integration of soft-sensor technologies with CHO-cell predictive models for improved bioreactor automation & process control
BIO Digital 2020
June 8-12, 2020
We will participate in partnering event and hold a corporate seminar about Advanced Control Bioreactor System.
Bushu Pharmaceuticals, Ltd., a major contract manufacturing company, is working to eliminate human error to ensure the integrity of test results data, and to promote reliable inspections and paperless operations.
Establish thorough quality assurance with state-of-the-art facilities and technologies to foster the future of medical products.
At Shionogi, the facility maintenance management system eHOZEN, the pr edecessor of eServ, has been used for about 10 years. However, due to the aging of servers and systems, they have begun considering renewing the system with the latest one. When considering this, suggestions from several vendors were received assuming that the system package safely migrates data assets accumulated on the current server and meets the following requirements:
The introduction of eServ has resulted in a centralized system of facility information. The reason for the loss of production opportunities has become clear, and it has become possible for all members to follow up the progress of the measures.
A critical requirement in biopharmaceutical development is the integration and automation of process equipment and analytical instruments used in the laboratory. Bioprocess labs with multiple lab-scale bioreactors often execute cultivation experiments in parallel for research or process development purposes.
As part of a collaboration between Securecell (Zurich, SW) and Yokogawa Life Science (Tokyo, Japan), this application note demonstrates the effective use of the Lucullus® Process Information Management System (Lucullus®) to assist in the control of three Advanced Control Bioreactor Systems (BR1000) to study glucose utilization of CHO cells for optimal monoclonal antibody productivity.
This application note will introduce the features of the SU10 and provide examples demonstrating the delivery of genome editing tools (Cas9 RNP) using the technology.
Exploring the technologies needed to achieve automatic control of cell culture processes.
Yokogawa Electric began offering the environmental monitoring system "OpreX Environmental Monitoring System" (hereinafter, OpreX EMS) for the pharmaceutical and medical device industries in October 2020. OpreX EMS, which was launched simultaneously domestically and overseas, is based on customers' needs, such as regulatory compliance, diversification of operational risks, and high usability. When asking the person in charge about the development history and features of the product, it was found that it is a new solution that meets the company's business vision.
- Confocal scanner unit CSU-W1 (2.9 MB)
- Confocal Scanner Unit CSU-W1 SoRa
- Single Cellome Unit SU10 (5.6 MB)
- Single Cellome System SS2000 Catalog (13.5 MB)
- Confocal scanner unit CSU-X1 (2.4 MB)
- High-throughput Cytological Discovery System CellVoyager CV8000 (2.5 MB)
- Confocal Quantitative Image Cytometer CQ1 (3.5 MB)
- High Content Analysis Software CellPathfinder (10.4 MB)
- Life Innovation Business (2.4 MB)
- High Content Data Management System CellLibrarian (747 KB)
The Yokogawa business vision states that the company endeavors to achieve Net-zero emissions, ensure the Well-being of all, and make a transition to a Circular Economy by 2050.
YOKOGAWA will contribute to technology evolution particularly in measurement and analytical tools to help build a world where researchers will increasingly focus on insightful interpretation of data, and advancing Life Science to benefit humanity.
Connecting MES and DCS in your pharma or biotech factory: Werum PAS-X MES and Yokogawa CENTUM VP
By equipping SMARTDAC+ with the advanced security features option "/AS", it meets the strict requirements of the U.S. FDA 21 CFR Part 11 and supports DI in compliance with PIC/S and ALCOA+ by WHO, MHRA and FDA.
Our approach is to leverage state-of-the-art technologies for real-time monitoring and predictive control that allow virtual environments where "digital twin" processes can provide distinct advantages.
YOKOGAWA aspires to establish Smart GMP manufacturing facilities that provide consistent quality and supply while eliminating industrial waste, enhancing productivity and always using high-quality component parts and materials.
YOKOGAWA creates autonomous operations with high-efficiency automation and optimization that allows growth with minimal deployment of manpower.
By adopting the environmental monitoring system, we were able to create an environment in the cell storage facility that allows for quality control, maintaining a high level of safety.
In this webinar, Professor Jonny Sexton discusses a pipeline, developed in the Sexton lab, for the quantitative high-throughput image-based screening of SARS-CoV-2 infection to identify potential antiviral mechanisms and allow selection of appropriate drug combinations to treat COVID-19. This webinar presents evidence that morphological profiling can robustly identify new potential therapeutics against SARS-CoV-2 infection as well as drugs that potentially worsen COVID-19 outcomes.
- Collaboration to widen use of N-NOSE cancer screening test -
- Supporting drug development research through the use of HCA and three-dimensional culture models -
Yokogawa Releases OpreX Environmental Monitoring System for Pharmaceutical and Medical Device Industries
- A system that ensures compliance with industry regulations and decreases risk to improve efficiency -
Yokogawa Acquires Fluid Imaging Technologies, a Provider of Flow Imaging Particle Analysis Solutions
- Enhancing our business in the bioeconomy market -
- Low invasiveness enables single-cell injection of target substances and extraction of intracellular materials -
Looking for more information on our people, technology and solutions?Contact Us